MedTrace Logo

Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer

NCT01051167 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2017-05-08

No results posted yet for this study

Summary

Cetuximab is normally given as a weekly schedule in the therapy of patients with metastatic colorectal cancer.

In order to improve the convenience for the patients in first line-therapy this study will evaluate the efficacy and safety of a bi-weekly combination of cetuximab with FOLFOX.

Conditions

Interventions

DRUG

Cetuximab

500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks

Sponsors & Collaborators

  • Martin Schuler, Prof. Dr. med.

    lead OTHER

Principal Investigators

  • Martin Schuler, Prof.Dr.med. · University of Duisburg-Essen Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01051167 on ClinicalTrials.gov